Fenwick & West represented Tamir Biotechnology, Inc., a clinical stage anti-viral therapeutics company engaged in the discovery and development of a new class of prophylactic and therapeutic drugs for the treatment of viruses and other pathological conditions, in the acquisition of its assets by Orgenesis Inc. (NASDAQ: ORGS).
The acquisition, which includes ranpirnase, TamirBio’s broad spectrum anti-viral platform, will be completed for a combination of stock and cash consideration.
Orgenesis plans to combine ranpirnase with its co-developed Bioxome technology for enhanced payload delivery directly to cells. More information can be obtained from the company’s announcement.
The Fenwick transaction team included corporate partner Ethan Skerry, associates Zachary Portnoy and Ammanuel Gebeyehu, and law clerk Elijah Porter; capital markets counsel Nicolas Dumont; executive compensation and employee benefits partner Matthew Cantor; technology transactions partner Stefano Quintini and counsel Claire O’Callaghan; and tax partner William Skinner and associate Ora Grinberg.